Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560129 | 1.00 | CYP3A4 (0.45) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL27488064 | 0.78 | MTOR (0.46) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL19973268 | 0.77 | ALDH1A1 (0.40) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL6114559 | 0.75 | CYP2D6 (0.50) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL28869351 | 0.74 | CYP3A4 (0.52) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL2390659 | 0.74 | CYP3A4 (0.52) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL30763462 | 0.74 | SIGMAR1 (0.61) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL283979 | 0.74 | SIGMAR1 (0.61) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL1200137 | 0.74 | SIGMAR1 (0.61) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 | |
| SCHEMBL8437895 | 0.74 | SIGMAR1 (0.61) | CYP3A4CYP2D6CHRM2ADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2121676-A1 | PREPERATION AND UTILITY OF CCR5 INHIBITORS | Auspex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008077103-A1 | PREPERATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146605-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146605-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146605-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | CCR5, CCR8, CCL5 | CYP3A4 468/4885CYP2D6 420/4885CHRM2 861/4885 |
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | CCR5, CCR8, CCL5 | CYP3A4 468/4885CYP2D6 420/4885CHRM2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.